source
- Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves aheadAurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program. The decision came just seven months after the company launched, and i…
- Early Alert: Intraosseous Needle Set Issue from Becton DickinsonBD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.